Jing Fan

Dr. Jing Fan received her bachelor ‘s degree at Peking University, Ph.D in Neuroscience at UBC, and postdoctoral training at Johns Hopkins University. She has been elected as one of the ’30 Global Innovative talents of Chinese entrepreneurs’ in 2018, the 2022 Forbes list “TOP50 Women in Science and Technology in China”, the “Outstanding founder in biotechnology industry of 2022” BioCon Award, etc. Dr. Jing Fan has more than 20 years of experience in the fields of pluripotent stem cell and neural differentiation, CNS diseases and drug discovery. She has published more than 10 academic papers and book chapters on top journals and led the Maryland Stem Cell Foundation project, and participated in major R&D projects such as NIH, Helis Foundation, etc. Since 2017, she has founded Hopstem, led the team to establish advanced CMC and development platform for iPSC-derived neural cell therapy products and raised more than 70 million USD. The global first-in-class human forebrain neural progenitor cell injection hNPC01 received IND clearance from FDA in 2024 and is undergoing a registered phase I clinical trial targeting chronic ischemic stroke in China.